Zobrazeno 1 - 10
of 67
pro vyhledávání: '"B. V. BIDERMAN"'
Autor:
A. N. Vasileva, O. A. Aleshina, E. S. Kotova, B. V. Biderman, T. N. Obukhova, I. V. Galtseva, V. N. Dvirnyk, E. I. Zakharko, A. B. Sudarikov, E. N. Parovichnikova
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 14-25 (2024)
Background. Current chemotherapy protocols for T-cell acute lymphoblastic leukemia (T-ALL) allow achieving a 5-year overall survival of 60–90 %, but relapsed and refractory forms remain incurable situations.Aim. To determine the significance of imm
Externí odkaz:
https://doaj.org/article/adedd1175d824e51baec49dd4a48c0c7
Publikováno v:
Онкогематология, Vol 18, Iss 3, Pp 92-101 (2023)
During aging phenotypic changes in the hematopoietic system occur, and possible reason of these changes can be accumulation of gene mutations in hematopoietic stem cells or early blood progenitors. Although these mutations are mostly neutral, some ma
Externí odkaz:
https://doaj.org/article/ef8eada3c6c44d948a733ed1ae7d2d22
Autor:
K. A. Pekhova, Yu. V. Sidorova, N. A. Severina, O. A. Glinshchikova, I. S. Fevraleva, B. V. Biderman, Yu. A. Chabaeva, S. M. Kulikov, I. A. Luk’yanova, A. I. Kashlakova, T. N. Obukhova, V. N. Dvirnyk, A. B. Sudarikov
Publikováno v:
Онкогематология, Vol 18, Iss 3, Pp 102-114 (2023)
Background. Tumor cell proliferation in acute myeloid leukemia (AML) may manifest with high leukocyte counts. In our work, we evaluate the association of high leukocyte counts with individual mutations, as well as their total contribution to the deve
Externí odkaz:
https://doaj.org/article/f6c43010c61f498ebdddc2d3c851444f
Publikováno v:
Онкогематология, Vol 17, Iss 4, Pp 166-176 (2022)
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is an aggressive hematological disease. Modern polychemotherapy protocols allow achieving a 5-year overall survival of 60–90 % in different age groups, however, relapses and refractory forms of T
Externí odkaz:
https://doaj.org/article/7d8182952b4e46ac855ef6dd695ff430
Autor:
Ye. А. Stadnik, Ye. А. Nikitin, B. V. Biderman, G. N. Salogub, Yu. Yu. Lorie, N. N. Tsyba, Yu. A. Alexeeva, V. A. Doronin, V. N. Mashuk, R. I. Vabishevich, A. L. Melikyan, T. I. Kolosheinova, L. Yu. Kolosova, A. B. Sudarikov, L. G. Kovaleva, A. Yu. Zaritsky
Publikováno v:
Онкогематология, Vol 0, Iss 1-2, Pp 39-46 (2022)
Preclinical studies showed synergic anti-tumor activity of Rituximab and Fludarabin. Comparison of efficacy of FC with FCR regimens administered in first line therapy and their influence on disease-free and overall survival in patients with B-cell ly
Externí odkaz:
https://doaj.org/article/00a0c2ea06324c9092c0197da79d94d1
Autor:
M. V. Demin, D. S. Tikhomirov, B. V. Biderman, M. Yu. Drokov, A. B. Sudarikov, T. A. Tupoleva, F. P. Filatov
Publikováno v:
Вопросы вирусологии, Vol 67, Iss 1, Pp 37-47 (2022)
Introduction. Infection caused by cytomegalovirus (CMV) is a serious problem for patients with weakened immunity, including patients with hematopoietic depression. The cases of complications associated with cytomegalovirus require antiviral therapy.
Externí odkaz:
https://doaj.org/article/beaff83fbe0b428cbe4f61a04e704992
Autor:
M. A. Kislitsyna, T. N. Obukhova, A. V. Kokhno, L. A. Grebenyuk, A. V. Luchkin, L. A. Kuzmina, V. N. Dvirnyk, A. M. Kovrigina, I. V. Galtseva, B. V. Biderman, V. V. Troitskaya, E. N. Parovichnikova
Publikováno v:
Онкогематология, Vol 14, Iss 3, Pp 69-76 (2019)
In chronic lymphocytic leukemia, the risk of second tumors including hematological malignancies, with which the use of purine nucleosides and alkylating agents in treatment of chronic lymphocytic leukemia is most often associated, is significantly in
Externí odkaz:
https://doaj.org/article/2c0272a5f1b14294822c10d7f61d9113
Autor:
T. V. SOROKINA, S. R. GORYACHEVA, V. A. SPIRINA, L. S. AL-RADI, T. N. OBUKHOVA, B. V. BIDERMAN, T. N. MOISEEVA
Publikováno v:
Медицинский совет, Vol 0, Iss 6, Pp 132-138 (2017)
Purpose of the study. To obtain experience with ibrutinib in patients with chronic lymphocytic leukemia (CLL) in everyday clinical practice.Material and methods. 20 patients with refractory or relapsed CLL were included in the study during the period
Externí odkaz:
https://doaj.org/article/5737387d7bbc4fcbb88c484d28eb1a73
Publikováno v:
Онкогематология, Vol 11, Iss 1, Pp 34-36 (2016)
DNA samples from patients with hairy cell leukemia (HCL) and splenic marginal zone B-cell lymphoma (MZBCL) for BRAF and MAP2K1 activating mutations were analyzed. V600E mutation of BRAF was detected in 39 (98 %) of 40 patients with hairy cell leukemi
Externí odkaz:
https://doaj.org/article/cd34210aeaeb40178877d059407a4fb0
Autor:
B. V. Biderman, E. A. Nikitin, T. F. Sergienko, A. V. Bakun, L. B. Taras, A. I. Svirnovskiy, A. B. Sudarikov
Publikováno v:
Онкогематология, Vol 7, Iss 3, Pp 38-42 (2014)
Mutation status of the heavy chain variable region genes has long been known as an important factor in long‑term prognosis in B‑cell chronic lymphocytic leukemia (B‑CLL). A more detailed study of the gene sequences of immunoglobulin heavy chain
Externí odkaz:
https://doaj.org/article/13da28bf7b3047c9a409735cc3bd34df